Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
ROSELAND, N.J., March 24, 2016 -- Emisphere (OTCQB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the twelve months ended December 31, 2015, on Tuesday, March 29, 2016, at 8:30 AM ET. A press release will be issued prior to market open.
The live webcast of the conference call can be accessed through the Company's web site at www.emisphere.com. The call can also be accessed by dialing (877) 303-9483 (United States and Canada) or (760) 666-3584 (international), and entering Conference ID# 76758582.
In addition, an archive of the webcast can be accessed through the same link and an audio replay of the call will be available beginning Tuesday, March 29, 2016 at 11:30 AM ET through 11:59 PM ET on April 18, 2016, by calling (855) 859-2056 (United States and Canada) or (404) 537-3406 (International), and entering Conference ID# 76758582.
About Emisphere
Emisphere is a pharmaceutical and drug delivery company. The Company launched its first prescription product, oral Eligen B12™, in the U.S. in March 2015. Beyond Eligen B12™, the Company utilizes its proprietary Eligen® Technology to create new oral formulations of therapeutic agents. Emisphere is currently partnered with global pharmaceutical companies for the development of new orally delivered therapeutics. For more information, please visit www.emisphere.com.
CONTACT: Alan L. Rubino, CEO 973.532.8000 [email protected] Michael R. Garone, CFO 973.532.8005 [email protected]
